Sales Activities of Generic Pharmaceutical Wholesalers and Expansion of Sales Areas through Subsidiarization

「The pharmaceutical wholesaling business continues to face a challenging operating environment owing to the rise in the cost ratio that has continued since April 2023. Under these conditions, results exceeded the previous-year period as the performance of the 3 companies newly added to the group since May 2025 contributed, while revenue at existing branches and sales offices also remained firm. As a result, revenue was ¥10,219 million, up 9.0% year on year, and operating income was ¥148 million, up 66.3%.」

「In the pharmaceutical wholesale business, Medical Ikko Co., Ltd., a core subsidiary of the group, acquired all shares of Kochi Daiichi Yakuhin Co., Ltd., which operates a pharmaceutical wholesale business in Kochi Prefecture, in May 2025. In July of the same year, it likewise acquired all shares of Saito Yakuhin Co., Ltd., which is based in Aichi Prefecture.」

「In the pharmaceutical wholesale business, the company continued to pursue group restructuring and new M&A. Specifically, during the interim consolidated accounting period, its core subsidiary, Medical Ikko Co., Ltd., absorbed and merged the 3 companies acquired in the fiscal year ending February 2025: Sato Yakuhin Hanbai Co., Ltd., Wakamatsu Yakuhin Co., Ltd. and Keiyo Sawai Yakuhin Co., Ltd. Meanwhile, in May of the current year, it acquired all shares of Kochi Daiichi Yakuhin Co., Ltd., which operates a pharmaceutical wholesale business in Kochi Prefecture, and in July of the same year acquired all shares of Saito Yakuhin Co., Ltd., which is based in Aichi Prefecture, making it a consolidated subsidiary (second-tier subsidiary).」

「In the pharmaceutical wholesale business, Medical Ikko Co., Ltd. made Sato Yakuhin Hanbai Co., Ltd. (head office: Kawaguchi, Saitama), Wakamatsu Yakuhin Co., Ltd. (head office: Takamatsu, Kagawa) and Keiyo Sawai Yakuhin Co., Ltd. (head office: Shibayama, Chiba) consolidated subsidiaries (second-tier subsidiaries) in October 2024 and January 2025, respectively.」

「In addition, in the pharmaceutical wholesale business, Medical Ikko Co., Ltd. entered into basic agreements with the shareholders of Sato Yakuhin Hanbai Co., Ltd., which has a sales base in Saitama and Chiba prefectures, and Wakamatsu Yakuhin Co., Ltd., which has a sales base in Kagawa and Tokushima prefectures, to acquire all of the shares of both companies in July of the same year.」

「In the pharmaceutical wholesale business, the operating environment has become increasingly challenging due to a sharp rise in the cost ratio since April of the previous year. The company focused on reviewing its organizational structure and strengthening its sales capabilities in order to realize the benefits of the September 2023 integration of its core subsidiary, Medical Ikko Co., Ltd., and Seibu Sawai Yakuhin Co., Ltd. As a result, revenue was ¥3,391 million, up 318.5% year on year, and operating profit was ¥94 million, up 313.4%.」

「On 1 September 2023, the group also integrated the pharmaceutical wholesale businesses of its core subsidiary, Medical Ikko Co., Ltd., and Seibu Sawai Yakuhin Co., Ltd. The company is currently focusing on restructuring its organization and strengthening its sales capabilities in order to realize the benefits of the integration at an early stage.」

「In addition, the group's overall network of locations has expanded to 1 prefecture, 2 metropolitan areas and 20 prefectures, mainly in the Tokai and western Japan regions.」

「In the pharmaceutical wholesale business, the market is expanding in line with measures to promote the use of generic drugs as part of healthcare system reform. The company will conduct detailed sales activities, expand distribution channels, mainly to medical institutions in Mie Prefecture, and continue developing business in Gifu, Shiga and Aichi prefectures.」

「In the pharmaceutical wholesale business, amid challenges in ensuring a stable supply of generic drugs, the company integrated its second-tier subsidiary into its core subsidiary in March 2022 and has continued strengthening its sales structure.」

「In the pharmaceutical wholesale business, amid challenges in ensuring a stable supply of generic drugs, Medical Ikko Co., Ltd., which plays a core role in the business, and its subsidiary Taiho Yakuhin Co., Ltd., a second-tier subsidiary of the company, were integrated in March 2022, and the company has been strengthening its sales structure.」

「In the pharmaceutical wholesale business, Medical Ikko Co., Ltd., which plays a core role in the pharmaceutical wholesale business as it does in the dispensing pharmacy business, and its subsidiary Taiho Yakuhin Co., Ltd., a second-tier subsidiary of the company, were integrated in March 2022. Amid challenges in ensuring a stable supply of generic drugs, the company is working to improve profitability by strengthening its sales structure and controlling expenses through integrated group operations.」

「In the pharmaceutical wholesale business, the decline in demand caused by constraints on sales activities and restrictions on outpatient medical care during the COVID-19 pandemic bottomed out, and the recovery trend continued. Profitability also improved as the company pursued cost reductions and greater efficiency. As a result, revenue was ¥2,129 million, up 8.3% year on year, and operating profit was ¥72 million, up 53.9%.」

「In the pharmaceutical wholesale business, the decline in demand caused by constraints on sales activities and restrictions on outpatient medical care that had continued from the previous fiscal year bottomed out and the business entered a recovery trend. Profitability also improved as the company pursued cost reductions and greater efficiency. As a result, revenue was ¥1,424 million, up 11.2% year on year, and operating profit was ¥50 million, up 140.6%.」

「In the pharmaceutical wholesale business, although constraints on sales activities caused by the prolonged COVID-19 pandemic and the impact of the drug price revision continued, conditions were gradually improving, with signs of easing restrictions on outpatient medical care. The company also pursued cost reductions and greater efficiency by consolidating its sales offices from 6 to 5 locations. As a result, revenue was ¥725 million, up 11.9% year on year, and operating profit was ¥35 million, up 121.0%.」

「In the pharmaceutical wholesale business, operating conditions remained challenging due to the impact of the April 2020 drug price revision, in addition to restrictions on outpatient medical care and sales activities associated with the spread of COVID-19. As a result, revenue was ¥1,967 million, down 1.8% year on year, and operating profit was ¥46 million, down 16.9%.」

「In the pharmaceutical wholesale business, operating conditions remained challenging due to the April 2020 drug price revision, restrictions on outpatient medical care associated with the spread of COVID-19, and restrictions on sales activities. As a result, revenue was ¥1,281 million, down 5.1% year on year, and operating profit was ¥20 million, down 49.7%.」

「In the pharmaceutical wholesale business, revenue and profit declined due to the impact of the drug price revision implemented in April 2020 and partial restrictions on sales activities resulting from the impact of COVID-19. As a result, revenue was ¥648 million, down 7.7% year on year, and operating profit was ¥16 million, down 42.7%.」

「In the pharmaceutical wholesale business, active sales efforts, including developing new business partners, resulted in higher revenue and profit. As a result, revenue was ¥2,003 million, up 7.2% year on year, and operating profit was ¥56 million, up 32.4%.」

「In the pharmaceutical wholesale business, active sales efforts, including developing new business partners and focusing on expanding sales of newly listed products, resulted in higher revenue and profit. As a result, revenue was ¥1,350 million, up 9.6% year on year, and operating profit was ¥41 million, up 29.7%.」

「In the pharmaceutical wholesale business, active sales efforts, including developing new business partners and focusing on expanding sales of newly listed products, resulted in higher revenue and profit. As a result, revenue was ¥702 million, up 12.2% year on year, and operating profit was ¥28 million, up 43.0%.」

「In the pharmaceutical wholesale business, the market is expanding in line with measures to promote the use of generic drugs as part of healthcare system reform. The company will conduct detailed sales activities, expand distribution channels, mainly to medical institutions in Mie Prefecture, and continue developing business in Gifu, Shiga and Aichi prefectures.」

「In the pharmaceutical wholesale business, revenue grew as a result of active sales efforts, but profit declined due to the drug price revision implemented in April 2018 and intensifying price competition. As a result, revenue was ¥1,869 million, up 4.8% year on year, and operating profit was ¥42 million, down 52.2%.」

「In the pharmaceutical wholesale business, revenue grew as a result of active sales efforts, mainly in Mie, Gifu, Shiga and Aichi prefectures, in response to the Ministry of Health, Labour and Welfare's measures to promote the use of generic drugs. However, profit declined due to the drug price revision implemented in April 2018 and intensifying price competition.」

「In the pharmaceutical wholesale business, revenue grew as a result of active sales efforts, mainly in Mie, Gifu, Shiga and Aichi prefectures, in response to the government's measures to promote the use of generic drugs. However, profit declined due to the drug price revision implemented in April 2018 and intensifying price competition. As a result, revenue was ¥626 million, up 5.5% year on year, and operating profit was ¥19 million, down 18.4%.」

「In the pharmaceutical wholesale business, active sales efforts, mainly in Mie, Gifu, Shiga and Aichi prefectures, in response to the government's measures to promote the use of generic drugs resulted in higher revenue and profit. As a result, revenue was ¥2,401 million, up 7.6% year on year, and operating profit was ¥117 million, up 38.8%.」

「In the pharmaceutical wholesaling business, active sales activities mainly in Mie, Gifu, Shiga and Aichi prefectures resulted in higher revenue and profit. As a result, revenue was ¥1,783 million, up 8.6% year on year, and operating profit was ¥88 million, up 70.8%.」

「In the pharmaceutical wholesaling business, active sales activities mainly in Mie, Gifu, Shiga and Aichi prefectures resulted in higher revenue and profit. As a result, revenue was ¥1,190 million, up 10.5% year on year, and operating profit was ¥64 million, up 58.3%.」

「In the pharmaceutical wholesaling business, active sales activities mainly in Mie, Gifu, Aichi and Shiga prefectures resulted in higher revenue. Profit increased only slightly, affected by market conditions in which price competition was intensifying. As a result, revenue was ¥594 million, up 11.5% year on year, and operating profit was ¥24 million, up 4.3%.」

「In the pharmaceutical wholesaling business, the market expanded in line with policies promoting generic pharmaceutical use, and sales increased as a result of active sales activities mainly in Mie, Gifu, Shiga and Aichi prefectures and contributions from the subsidiary brought into the group in April.」

「The company conducted active sales activities mainly in Mie, Gifu, Shiga and Aichi prefectures and expanded its sales area by making 大豊薬品株式会社 a subsidiary in April 2016. As a result, revenue was ¥1,076 million, up 53.4% year on year, and operating profit was ¥40 million, up 14.4%.」

「As the market expanded in line with policies promoting the use of generic pharmaceuticals, the company conducted active sales activities mainly in Mie, Gifu and Shiga prefectures. In April 2016, it made 大豊薬品株式会社, which sells generic pharmaceuticals mainly in Aichi Prefecture, a subsidiary to expand its sales area.」